Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading on Wednesday. Traders purchased 30,719 call options on the stock. This represents an increase of approximately 87% compared to the typical daily volume of 16,400 call options.

Insider Activity

In related news, CEO Najat Khan sold 23,588 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock worth $478,874 in the last quarter. 6.65% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at $31,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $39,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. MQS Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, Fund Advisors of America Inc FL purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $45,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Finally, Wall Street Zen lowered Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.06.

Recursion Pharmaceuticals Stock Down 2.0%

Recursion Pharmaceuticals stock opened at $3.49 on Thursday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -3.36 and a beta of 1.03. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18. The business’s 50-day moving average price is $3.31 and its 200 day moving average price is $3.35. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same period in the previous year, the firm posted ($0.41) earnings per share. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals will post -0.92 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.